Apellis Pharmactdl 0001 Stock Earnings Per Share
| 1JK Stock | EUR 27.76 0.94 3.28% |
APELLIS PHARMACTDL 0001 fundamentals help investors to digest information that contributes to APELLIS PHARMACTDL's financial success or failures. It also enables traders to predict the movement of APELLIS Stock. The fundamental analysis module provides a way to measure APELLIS PHARMACTDL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to APELLIS PHARMACTDL stock.
APELLIS |
APELLIS PHARMACTDL 0001 Company Earnings Per Share Analysis
APELLIS PHARMACTDL's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current APELLIS PHARMACTDL Earnings Per Share | (7.48) X |
Most of APELLIS PHARMACTDL's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, APELLIS PHARMACTDL 0001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, APELLIS PHARMACTDL 0001 has an Earnings Per Share of -7.483 times. This is 189.4% lower than that of the Healthcare sector and 56.22% higher than that of the Biotechnology industry. The earnings per share for all Germany stocks is notably higher than that of the company.
APELLIS Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses APELLIS PHARMACTDL's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of APELLIS PHARMACTDL could also be used in its relative valuation, which is a method of valuing APELLIS PHARMACTDL by comparing valuation metrics of similar companies.APELLIS PHARMACTDL is currently under evaluation in earnings per share category among its peers.
APELLIS Fundamentals
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (4.60) % | |||
| Shares Outstanding | 110.58 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 89.16 % | |||
| Revenue | 113.05 M | |||
| Gross Profit | (253.92 M) | |||
| EBITDA | (518.43 M) | |||
| Net Income | (460.28 M) | |||
| Cash And Equivalents | 599.01 M | |||
| Cash Per Share | 6.89 X | |||
| Total Debt | 409.63 M | |||
| Debt To Equity | 7.94 % | |||
| Current Ratio | 4.15 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (239.85 M) | |||
| Earnings Per Share | (7.48) X | |||
| Target Price | 67.81 | |||
| Number Of Employees | 767 | |||
| Beta | 1.23 | |||
| Market Capitalization | 5.78 B | |||
| Z Score | 8.4 |
About APELLIS PHARMACTDL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze APELLIS PHARMACTDL 0001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of APELLIS PHARMACTDL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of APELLIS PHARMACTDL 0001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.